| Stereochemistry | ACHIRAL |
| Molecular Formula | C15H9ClO2 |
| Molecular Weight | 256.684 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
ClC1=CC=C(C=C1)C2C(=O)C3=C(C=CC=C3)C2=O
InChI
InChIKey=NJDUWAXIURWWLN-UHFFFAOYSA-N
InChI=1S/C15H9ClO2/c16-10-7-5-9(6-8-10)13-14(17)11-3-1-2-4-12(11)15(13)18/h1-8,13H
| Molecular Formula | C15H9ClO2 |
| Molecular Weight | 256.684 |
| Charge | 0 |
| Count |
MOL RATIO
1 MOL RATIO (average) |
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
Approval Year
PubMed
Patents
Sample Use Guides
32 patients were treated in hospital and administered oral tablets of clorindione; 12 mg on the first day, 8 mg on the second day, and 4 mg on the third day. Because of the delayed action of clorindione, Heparin 10,000 iu was given by intramuscular injection on admission and then 5,000 iu every 6 hours for 3 days at 24-hour intervals. Clorindione effectively reduced the prothrombin levels in the patient population back to the desired therapeutic range by the fourth day.
Route of Administration:
Oral
